TransCode Therapeutics, Inc. Common Stock
RNAZTransCode Therapeutics, Inc. (RNAZ) is a biotechnology company focused on developing RNA-based therapeutics for cancer and other diseases. The company utilizes innovative platforms to identify and validate RNA targets, aiming to create precision medicines that can modulate disease-driving genes. TransCode's approach involves advanced technologies such as proprietary delivery systems and genetic targeting methods to enhance the effectiveness of RNA therapeutics.
Company News
A comprehensive market report on checkpoint inhibitors covering 50+ companies and 60+ drugs in oncology. The report highlights key players like Bristol Myers Squibb, Genentech, and emerging companies such as OncoC4 and Transcode Therapeutics, with analysis of marketed therapies, pipeline products, and recent industry collaborations and acquisitio...
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors. Stover brings over 30 years of executive leadership experience in life sciences, drug development, and capital formation. He will join the Audit and Nominating Committees as the company advances its RNA and immuno-oncology pipeline for can...
TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology firm focused on immuno-oncology, and received a $25 million strategic investment from CK Life Sciences. The deal includes stock issuance and will support the advancement of TransCode's microRNA-based therapeutic into Phase 2 clinical trials.
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.
